The acquisition of myPOLS Biotec complements Medix Biochemica’s leading portfolio of IVD raw materials and expands its reagent offerings for molecular diagnostics
The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
The new manufacturing facility will be built at a subsidiary of Adcock Ingram and will commence operation in March 23
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
The agreement will sharpen Cigna's focus on the growth path for its rapidly expanding global health portfolio
The new devices company will scale up its teams to create a world-class R&D centre for medical devices in India
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
Subscribe To Our Newsletter & Stay Updated
